Advanced Wound Dressings Patents: Who Leads, Where the Gaps Are 2026
- 38.1% of filings sit with the top 5. of the 21 records in scope, so a small cluster of assignees holds the largest single share but well under half — leaving substantial room for new entrants.
- Sterilising and disinfecting dominates. A61L appears in 85.7% of records, far ahead of medicinal preparations (42.9%) and implants (33.3%), showing where claim density is heaviest.
- India leads receiving offices 15 to 4 to 2. against WIPO (PCT) and the United States, pointing to where filing activity is concentrated and where jurisdictional coverage is thinner.
Filing growth compares 2021 (2 records) with 2024 (0) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 21 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This landscape covers 21 published records matching advanced wound dressing and wound hydrogel dressing terms combined with moisture balance, exudate handling, adhesive trauma, conformability, wear time and gel-formation language. The scope spans filings from 2015 through the 2026-07-31 data cut-off, with 34 companies appearing in the assignee ranking. Receiving-office data shows India as the dominant jurisdiction, followed by WIPO PCT filings and the United States.
Because publication lags filing by roughly 18 months, the most recent one to two years in any trend understate real filing activity. Family-level counting is used throughout so that multi-jurisdiction and continuation filings do not distort the picture of who is actually active.
Filing trend and technology composition
The trend line and IPC breakdown below are drawn directly from the 21 records in scope; class shares sum to more than 100% because a single record can carry several IPC classes.
Filing trend, 2017-2026
Filings rose from zero in 2017 to a peak of 7 in 2025, though 2021 to 2024 shows a -100% swing on a small base — a reminder that early counts move sharply on low volumes rather than signalling a durable slowdown. 2026 figures are partial and will revise upward as publication catches up with filing.
IPC subclass composition
A61L (sterilising and disinfecting) covers 85.7% of the 21 records, making it the densest claim territory by a wide margin. A61K (medicinal preparations) and A61F (implants and prostheses) follow at 42.9% and 33.3%, while polysaccharide-based chemistry under C08B appears in just 9.5% of records — one of the thinner corners of the field.
Shares are the percentage of the 21 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Advanced Wound Dressings and Hydrogels with Eureka
This page is one run against one query. Ask Eureka your own question about advanced wound dressings and hydrogels and every answer comes back with the patent numbers behind it.
Try EurekaMost-cited records in this dataset
Unique combination of natural biopolymers for advanced wound dressing
The filing describes a wound dressing built on a biopolymer scaffold, such as a keratin-based scaffold, combined with collagen-based materials to increase mechanical strength. The biopolymer combination is designed to extend retention time in the wound environment, supporting progression through the inflammatory phase and acting as a structural scaffold for tissue integration.US20210146002A1 — filed by Solventum Intellectual Properties Company, published 2021-05-20.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2018218096A1 | Multi-layered system for wound healing along with methods of its formation and use | 6 |
| 2 | US20210146002A1 | Unique combination of natural biopolymers for advanced wound dressing | 1 |
Citation counts reflect influence within the searched corpus and favour older filings; they are not a measure of current commercial importance.
Publication numbers are shown where the record carries one (2 of 2 rows); clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for filing strategy
Three patterns stand out once the records are broken down by concentration, technology class and jurisdiction.
Leadership is present but not dominant
The top 5 assignees combined account for 38.1% of the 21 records in scope, and the top 10 for 61.9%. That leaves over a third of filings spread across a long tail of single- or double-filing entrants, none of whom has built a blocking position.
Sterilising and disinfecting claims crowd the field
A61L appears in 85.7% of records, well ahead of every other class. New filings aimed squarely at sterilising or disinfecting mechanisms are entering the most contested part of the landscape; claims built around polysaccharide chemistry (C08B, 9.5%) or vinyl-addition polymers (C08F, 4.8%) face far less prior art.
Filing activity concentrates in one office
India accounts for 15 of the records in scope, against 4 through WIPO PCT and 2 in the United States. Anyone building a global filing strategy in this space should treat US and PCT coverage as comparatively open relative to the volume already on file in India.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to advanced wound dressings and hydrogels, with the prior art for and against each one.
Who is filing, and where the activity sits today
The assignee ranking covers 34 companies counted by record; no single filer accounts for more than a handful of the 21 records in scope, and recent-year momentum is thin across the board.
The top filer holds a small lead, not a moat
The leading assignee accounts for 3 of the 21 records, with the fifth-ranked and tenth-ranked assignees each holding just 1. That gap between first place and the rest of the ranked list is narrow, which is unusual for a field with this much claim density in one IPC class.
Recent activity is dispersed, not renewed by the leader
In the most recent year, activity comes from assignees such as Saveetha Institute of Medical & Technical Sciences and Vellore Institute of Technology, each with 1 filing, while the historic leader shows 0 in the latest year. That pattern suggests leadership by filing count does not currently translate into leadership on recent momentum.
Co-filing is limited and clustered around one inventor group
Only 4 co-assignee pairs appear across the dataset, and the strongest repeated pairing centres on a single named inventor filing alongside different co-inventors. This points to a field still dominated by solo institutional filers rather than established joint-development programmes.
| Assignee | Recent year | YoY |
|---|---|---|
| SAVEETHA INST OF MEDICAL & TECH SCI | 1 | 0% |
| VELLORE INSITUTE OF TECH | 1 | — |
| LIFECELL INT PVT LTD | 0 | — |
| KCI Licensing, Inc. | 0 | — |
| King Abdullah University of Science and Technology | 0 | — |
| Indian Institute of Technology Hyderabad | 0 | -100% |
| Indian Institute of Technology Indore | 0 | -100% |
| Medical University of South Carolina Foundation for Research Development | 0 | — |
Where to take this analysis
The dataset points to specific next steps depending on whether the goal is freedom-to-operate, portfolio benchmarking or identifying open claim territory.
Map claims against the A61L cluster
With 85.7% of records touching sterilising and disinfecting claims, a freedom-to-operate review should start there before extending to the thinner classes.
Explore claim mapping in EurekaTrack momentum beyond the historic leader
Recent-year filings are coming from newer institutional entrants rather than the top-ranked assignee, which changes who should be watched going forward.
Set up assignee monitoring in EurekaTest white space in polysaccharide and vinyl-polymer claims
C08B and C08F each cover under 10% of records, suggesting these chemistry routes remain comparatively open for new claim construction.
Run a white-space search in EurekaFrequently asked questions
Among the 34 companies in the assignee ranking, the leading assignee holds 3 of the 21 records in scope, with the fifth- and tenth-ranked assignees each holding just 1. The top 5 assignees combined account for 38.1% of records and the top 10 for 61.9%, meaning leadership exists but no single filer controls the field. A large share of activity comes from academic and research institutions rather than established medical device manufacturers.
Sterilising and disinfecting technology under IPC class A61L appears in 85.7% of the 21 records, making it by far the most heavily claimed area. Medicinal preparations (A61K) and implants or prostheses (A61F) follow at 42.9% and 33.3% respectively. Polysaccharide-based chemistry and vinyl-addition polymer approaches each appear in under 10% of records, indicating comparatively less-crowded claim space there.
Filings rose from zero in 2017 to a peak of 7 in 2025, but a -100% swing from 2021 to 2024 reflects a small base rather than a genuine collapse in interest. Because publication lags filing by roughly 18 months, 2025 and 2026 figures are still incomplete and will revise upward. The honest read is that recent-year trend data cannot yet support a firm growing-or-slowing conclusion.
India accounts for 15 of the 21 records in scope, making it the dominant receiving office by a wide margin. WIPO PCT applications account for 4 records and the United States for 2. This distribution suggests that global coverage outside India, particularly in the US, remains comparatively thin relative to the volume of filings already on record there.
US20210146002A1 describes a wound dressing built on a biopolymer scaffold, such as a keratin-based scaffold, combined with collagen-based materials to increase mechanical strength and extend retention time in the wound environment. It is one of the most-cited records in this dataset, filed by Solventum Intellectual Properties Company. Anyone developing biopolymer scaffold dressings for extended wear time should review its claims closely before finalising a competing formulation.
Research Advanced Wound Dressings and Hydrogels in depth with Eureka
Go past this page: query the whole advanced wound dressings and hydrogels corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.